LCTX Stock Overview A clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Lineage Cell Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Lineage Cell Therapeutics Historical stock prices Current Share Price US$0.56 52 Week High US$1.61 52 Week Low US$0.48 Beta 1.16 1 Month Change -13.00% 3 Month Change -40.64% 1 Year Change -48.81% 3 Year Change -79.18% 5 Year Change -27.53% Change since IPO -83.67%
Recent News & Updates Lineage Cell Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $30.000003 million. Nov 22
Lineage Cell Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $30.000003 million. Nov 21
New minor risk - Share price stability Nov 21 Lineage Cell Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $30.000003 million. Nov 20
New major risk - Revenue and earnings growth Nov 18
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 15 See more updates Lineage Cell Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $30.000003 million. Nov 22
Lineage Cell Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $30.000003 million. Nov 21
New minor risk - Share price stability Nov 21 Lineage Cell Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $30.000003 million. Nov 20
New major risk - Revenue and earnings growth Nov 18
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 15
Lineage Cell Therapeutics, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Nov 07
Lineage Cell Therapeutics, Inc. Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance, at the 59th Annual Inner Ear Biology Workshop Sep 19
New minor risk - Profitability Aug 12
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 09
Lineage Cell Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Consensus revenue estimates decrease by 30% May 16
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind May 10
Lineage Cell Therapeutics, Inc. Announces 24 Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit May 07
Lineage Cell Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Insufficient new directors May 01
Lineage Cell Therapeutics, Inc. Announces Changes to Board of Directors Apr 30 Lineage Cell Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $40 million. Mar 23
Consensus revenue estimates fall by 12% Mar 17
New minor risk - Profitability Mar 11
No longer forecast to breakeven Mar 11
Lineage Cell Therapeutics, Inc. Announces Preclinical Engraftment Results to Be Presented At 2024 Association for Research in Vision and Ophthalmology Meeting Mar 11
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 08
Lineage Cell Therapeutics, Inc. to Report Q4, 2023 Results on Mar 07, 2024 Mar 01
Lineage Cell Therapeutics, Inc., Annual General Meeting, Jun 11, 2024 Feb 16
Lineage Announces FDA Clearance of IND Amendment for Opc1 Cell Transplant for the Treatment of Spinal Cord Injury Feb 14
Independent Director recently bought US$100k worth of stock Feb 10 Lineage Cell Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $14.000002 million. Feb 06
Forecast to breakeven in 2026 Dec 31
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury Dec 18
Consensus revenue estimates decrease by 14% Nov 16
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 10
Lineage Cell Therapeutics, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 02
Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Oct 17
Lineage Cell Therapeutics, Inc. Announces Results of Imaging Analyses Demonstrating Rapid Improvement in Outer Retinal Structure from Patients Enrolled in A Phase 1/2A Clinical Study of RG6501 Oct 06
Lineage Cell Therapeutics, Inc. Announces the Results of Imaging Analyses Demonstrating Evidence of Rapid Improvement in Outside Retinal Structure from A Phase 1/2A Clinical Study of Rg6501 Sep 14
Consensus revenue estimates increase by 11% Aug 17
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 11
Lineage Cell Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
Lineage Cell Therapeutics and Cancer Research UK Reports Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer Jul 25
New minor risk - Shareholder dilution Jul 13
Consensus revenue estimates increase by 18%, EPS downgraded Jul 09
Lineage Cell Therapeutics, Inc., Annual General Meeting, Sep 06, 2023 Jun 22
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 13
Lineage Cell Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 11
Forecast to breakeven in 2025 Mar 10
Price target decreased by 10.0% to US$5.40 Feb 16
Lineage Cell Therapeutics, Inc. Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss Feb 09
Lineage Announces Launch of Phase 2A Study by Genentech of RG6501 (OpRegen®) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration Nov 29
Consensus forecasts updated Nov 17
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 16
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 12
Lineage Cell Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 04
Lineage Cell Therapeutics, Inc Appoints Jill A. Howe as Chief Financial Officer, Effective November 14, 2022 Nov 01
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 12
Lineage Cell Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 05 Lineage Cell Therapeutics, Inc. Announces Chief Financial Officer Changes Lineage Cell Therapeutics, Inc.(NYSEAM:LCTX) dropped from Russell 2000 Value Index
Consensus revenue estimates fall by 22% May 19
First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 13
Lineage Cell Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022 May 06
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration May 04
Price target increased to US$6.50 Apr 27
No longer forecast to breakeven Apr 27
Lineage Cell Therapeutics, Inc. Announces A Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness Apr 26
Lineage Cell Therapeutics, Inc. and Cancer Research UK Announce Completion of Patient Enrollment in Phase 1 Clinical Study of Vac2 for the Treatment of Non-Small Cell Lung Cancer Apr 14
Independent Director recently bought US$57k worth of stock Apr 05
Consensus revenue estimates increase by 54% Mar 17
No longer forecast to breakeven Mar 16
Full year 2021 earnings: EPS and revenues exceed analyst expectations Mar 12
Lineage Cell Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022 Mar 03
Forecast to breakeven in 2024 Feb 16
Insider exercised options and sold US$527k worth of stock Dec 31
Insider recently sold US$69k worth of stock Dec 31
Lineage Cell Therapeutics, Inc. Reports Fourth Case of Retinal Tissue Restoration with Opregen® Dec 02
Third quarter 2021 earnings released: US$0.047 loss per share (vs US$0.052 loss in 3Q 2020) Nov 12
Consensus revenue estimates fall to US$2.04m Aug 19
Second quarter 2021 earnings released: US$0.029 loss per share (vs US$0.044 loss in 2Q 2020) Aug 13
Lineage Cell Therapeutics, Inc. Announces Updated Interim Results from Phase 1/2a Study of its Lead Product Candidate, OpRegen Jul 15
Independent Director exercised options to buy US$69k worth of stock. Jun 24
Lineage Cell Therapeutics, Inc. Provides an Update on the Clinical Advancement of OPC1 Jun 23
Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration in Dry Amd Patients Treated with Opregen Rpe Cells Jun 02
Consensus forecasts updated May 18
Forecast to breakeven in 2024 May 15
First quarter 2021 earnings released: US$0.009 loss per share (vs US$0.056 loss in 1Q 2020) May 15
Lineage Cell Therapeutics, Inc. Announces Updated Interim Results from Its Ongoing, 24-Patient Phase 1/2A Clinical Study of Its Lead Product Candidate, Opregen May 04
General Counsel & Corporate Secretary has left the company Apr 08
Consultant notifies of intention to sell stock Mar 21 Shareholder Returns LCTX US Biotechs US Market 7D 10.3% -5.6% -3.5% 1Y -48.8% -1.5% 22.1%
See full shareholder returns
Return vs Industry: LCTX underperformed the US Biotechs industry which returned -1.5% over the past year.
Return vs Market: LCTX underperformed the US Market which returned 22.1% over the past year.
Price Volatility Is LCTX's price volatile compared to industry and market? LCTX volatility LCTX Average Weekly Movement 13.5% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: LCTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: LCTX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.
Show more Lineage Cell Therapeutics, Inc. Fundamentals Summary How do Lineage Cell Therapeutics's earnings and revenue compare to its market cap? LCTX fundamental statistics Market cap US$110.65m Earnings (TTM ) -US$20.11m Revenue (TTM ) US$8.72m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LCTX income statement (TTM ) Revenue US$8.72m Cost of Revenue -US$2.31m Gross Profit US$11.03m Other Expenses US$31.14m Earnings -US$20.11m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.091 Gross Margin 126.54% Net Profit Margin -230.66% Debt/Equity Ratio 0%
How did LCTX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 22:58 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Lineage Cell Therapeutics, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jack Allen Baird Mayank Mamtani B. Riley Securities, Inc. Gum-Ming Lowe Craig-Hallum Capital Group LLC
Show 8 more analysts 
